Ark signs South Korean sales deal for Kerraboot ulcer device:
This article was originally published in Clinica
Ark Therapeutics, of London, UK, has signed an exclusive marketing agreement for its Kerraboot leg and foot ulcer management device in South Korea. Local healthcare products distributor BL&H Co has acquired sales and marketing rights in return for a double-digit royalty to Ark. BL&H Co will be responsible for securing product reimbursement from the South Korean regulators. According to Ark, there are about 2 million diabetics in the country, of whom 300,000 could be expected to have a leg or foot ulcer at any one time.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.